| Literature DB >> 31533045 |
Timothy S C Hinks1, Emanuele Marchi2, Maisha Jabeen3, Moshe Olshansky4, Ayako Kurioka2, Troi J Pediongco5, Bronwyn S Meehan5, Lyudmila Kostenko5, Stephen J Turner6, Alexandra J Corbett5, Zhenjun Chen5, Paul Klenerman7, James McCluskey5.
Abstract
Mucosal-associated invariant T (MAIT) cells are MR1-restricted innate-like T cells conserved across mammalian species, including mice and humans. By sequencing RNA from sorted MR1-5-OP-RU tetramer+ cells derived from either human blood or murine lungs, we define the basic transcriptome of an activated MAIT cell in both species and demonstrate how this profile changes during the resolution of infection and during reinfection. We observe strong similarities between MAIT cells in humans and mice. In both species, activation leads to strong expression of pro-inflammatory cytokines and chemokines as well as a strong tissue repair signature, recently described in murine commensal-specific H2-M3-restricted T cells. Transcriptomes of MAIT cells and H2-M3-specific CD8+ T cells displayed the most similarities to invariant natural killer T (iNKT) cells when activated, but to γδ T cells after the resolution of infection. These data define the requirements for and consequences of MAIT cell activation, revealing a tissue repair phenotype expressed upon MAIT cell activation in both species.Entities:
Keywords: MHC-related protein 1; T cell; activation; human; lung; mouse; mucosal-associated invariant T cell; riboflavin; tissue repair; transcriptome
Mesh:
Year: 2019 PMID: 31533045 PMCID: PMC6859474 DOI: 10.1016/j.celrep.2019.07.039
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423
Figure 1Costimulatory Requirements for MAIT Cell Activation In Vivo
(A) Representative flow-cytometry plots showing MAIT cell percentage among TCRβ+ lymphocytes in the lungs of C57BL/6 mice with or without prior stimulation with intranasal CpG and 5-OP-RU.
(B and C) Relative (B) and absolute (C) numbers of MR1-5-OP-RU tetramer+ MAIT cells in the lungs of C57BL/6 mice 7 days after intranasal exposure to specific TLR agonists either alone or in combination with 76 pmol 6-FP, or with 76 pmol 5-OP-RU. Control mice received nothing (n = 4, naive) or CpG with 5-OP-RU (n = 3). Experiments used n = 5 (5-OP-RU treated), n = 3 (6-FP treated), or n = 2 (TLR agonist alone) mice per group. The experiment was subsequently repeated with similar results. Statistical tests: unpaired t tests, comparing TLR + 5-OP-RU with naive control (n = 4), on untransformed (B) or log-transformed (C) data with Bonferroni corrections ∗p < 0.05, ∗∗∗p < 0.001.
Differentially Expressed Cytokine Genes: Human
| Stimulated MAIT versus Unstimulated CD8+45RA+ | Stimulated MAIT versus Unstimulated MAIT | Unstimulated MAIT versus Unstimulated CD8+45RA+ | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gene | Log Fold Change | Log CPM | LR | p Value | FDR p Value | Gene | Log Fold Change | Log CPM | LR | p Value | FDR p Value | Gene | Log Fold Change | Log CPM | LR | p Value | FDR p Value |
| CSF2 | 15 | 7.4 | 62 | 3E−15 | 0.00 | CSF2 | 15 | 7.4 | 64 | 1E−15 | 0.00 | LIF | 4.7 | 1.8 | 7.2 | 0.007 | 0.02 |
| IL17A | 12 | 4.9 | 74 | 8E−18 | 0.00 | IL17A | 12 | 4.9 | 77 | 1E−18 | 0.00 | TGFA | 4.4 | 3.3 | 43 | 6E−11 | 0.00 |
| IL2 | 11 | 4.0 | 42 | 1E−10 | 0.00 | IFNG | 9.7 | 8.4 | 61 | 6E−15 | 0.00 | TNF | 2.4 | 9.0 | 7.9 | 0.005 | 0.02 |
| LIF | 8.9 | 1.8 | 26 | 3E−07 | 0.00 | IL17F | 8.3 | 1.2 | 35 | 3E−09 | 0.00 | TNFSF13B | 2.3 | 3.3 | 9.5 | 0.002 | 0.01 |
| TNF | 8.7 | 9.0 | 59 | 2E−14 | 0.00 | IL2 | 8.0 | 4.0 | 33 | 1E−08 | 0.00 | TNFSF14 | 2.1 | 8.0 | 22 | 2E−06 | 0.00 |
| IFNG | 8.4 | 8.4 | 51 | 1E−12 | 0.00 | TNF | 6.3 | 9.0 | 38 | 8E−10 | 0.00 | CSF1 | 2.0 | 5.1 | 21 | 7E−06 | 0.00 |
| IL17F | 8.3 | 1.2 | 32 | 1E−08 | 0.00 | LIF | 4.2 | 1.8 | 12 | 0.0005 | 0.00 | IL15 | 1.9 | 2.3 | 5.8 | 0.02 | 0.04 |
| TNFSF14 | 5.3 | 8.0 | 113 | 2E−26 | 0.00 | IL10 | 4.1 | 1.5 | 14 | 0.0002 | 0.00 | IL24 | −1.8 | 2.4 | 6.2 | 0.01 | 0.04 |
| CSF1 | 5.2 | 5.1 | 120 | 7E−28 | 0.00 | TNFSF14 | 3.2 | 8.0 | 52 | 6E−13 | 0.00 | CXCR2 | −4.0 | 3.0 | 9.7 | 0.001 | 0.01 |
| IL26 | 4.6 | 1.8 | 16 | 7E−05 | 0.00 | CSF1 | 3.2 | 5.1 | 59 | 2E−14 | 0.00 | CXCR1 | −4.1 | 2.6 | 14 | 0.0001 | 0.00 |
| LTA | 3.3 | 7.0 | 48 | 4E−12 | 0.00 | LTA | 3.1 | 7.0 | 43 | 7E−11 | 0.00 | ||||||
| TGFA | 2.9 | 3.3 | 19 | 1E−05 | 0.00 | IL16 | −1.1 | 9.3 | 5.6 | 0.018 | 0.04 | ||||||
| TNFSF13B | 2.6 | 3.2 | 12 | 0.0004 | 0.00 | TGFA | −1.6 | 3.3 | 7.4 | 0.006 | 0.02 | ||||||
| IL23A | 2.3 | 4.7 | 12 | 0.0004 | 0.00 | IL32 | −1.6 | 9.7 | 20 | 8.1E−06 | 0.00 | ||||||
| IL32 | −1.2 | 9.7 | 12 | 0.0005 | 0.00 | IL18BP | −3.0 | 5.1 | 40 | 2.9E−10 | 0.00 | ||||||
| IL16 | −1.5 | 9.3 | 11 | 0.001 | 0.00 | CXCR1 | −5.7 | 2.6 | 13 | 0.0004 | 0.00 | ||||||
| IL24 | −2.0 | 2.4 | 7.7 | 0.005 | 0.01 | ||||||||||||
| IL18BP | −3.6 | 5.1 | 57 | 6E−14 | 0.00 | ||||||||||||
| CXCR2 | −4.9 | 3.0 | 13 | 0.0002 | 0.00 | ||||||||||||
| CXCR1 | −9.8 | 2.6 | 37 | 1E−09 | 0.00 | ||||||||||||
Genes shown are censored at FDR p ≤ 0.05 and log(2) fold change of ±1 and ordered by log fold change. CPM, counts per million; FDR, false discovery rate; LR, likelihood ratio.
Genes are differentially expressed in both humans and mice.
Differentially Expressed Cytokine Genes: Mouse
| Acute Infection MAIT Cells versus Uninfected CD8+44Lo62Hi | Resolved Infection MAIT Cells versus Acute Infection MAIT cells | Reinfection MAIT Cells versus Acute Infection MAIT Cells | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gene | Log Fold Change | Log CPM | LR | p value | FDR p Value | Gene | Log Fold Change | Log CPM | LR | p Value | FDR p Value | Gene | Log Fold Change | Log CPM | LR | p Value | FDR p Value |
| Il17a | 14 | 7.3 | 316 | 9E−71 | 1E−68 | Tnfsf18 (GITRL) | 5.9 | −0.52 | 14 | 0.0002 | 0.001 | Csf1 (M-CSF) | 2.2 | 3.0 | 12 | 0.0006 | 0.01 |
| Ifng | 12 | 5.9 | 222 | 3E−50 | 2E−48 | Tnfsf11 (TRANCE) | 3.2 | 6.6 | 67 | 3E−16 | 4E−14 | Il6st | 1.5 | 6.7 | 14 | 0.0002 | 0.005 |
| Csf2 | 11 | 4.8 | 208 | 4E−47 | 3E−45 | Il15 | 1.9 | 0.88 | 6.7 | 0.0096 | 0.03 | Tnsf11 (TRANCE) | 1.3 | 6.6 | 14 | 0.0002 | 0.007 |
| Il17f | 11 | 4.9 | 171 | 5E−39 | 2E−37 | Tgfb3 | 1.4 | 4.0 | 16 | 6E−05 | 0.0005 | Il17a | –1.5 | 7.3 | 15 | 9.7E–05 | 0.003 |
| Lif | 10 | 3.6 | 132 | 1E−30 | 5E−29 | Il6st | 1.3 | 6.7 | 9.9 | 0.002 | 0.008 | Csf4 | –1.2 | 4.8 | 12 | 0.0006 | 0.01 |
| Il22 | 9.1 | 2.4 | 43 | 4E−11 | 4E−10 | Il17f | 1.1 | 4.9 | 8.5 | 0.004 | 0.02 | ||||||
| Il21 | 7.5 | 0.65 | 23 | 2E−06 | 1E−05 | Il21 | −3.8 | 0.65 | 11 | 0.0008 | 0.005 | ||||||
| Tnf | 4.5 | 6.0 | 188 | 1E−42 | 6E−41 | Il17a | −2.4 | 7.3 | 38 | 9E−10 | 38E−08 | ||||||
| Lta (TNFb/lymphotoxin A) | 3.8 | 6.2 | 110 | 9E−26 | 3E−24 | Ifng | −2.4 | 5.9 | 35 | 3E−09 | 8E−08 | ||||||
| Il1b | 2.6 | 4.5 | 6.2 | 0.01 | 0.03 | Tnfsf10 (TRAIL) | −1.6 | 4.0 | 19 | 2E−05 | 0.0002 | ||||||
| Tnfsf11 (TRANCE) | 2.3 | 6.6 | 35 | 3E−09 | 2E−08 | Lif | −1.4 | 3.6 | 11 | 0.0009 | 0.005 | ||||||
| Csf1 (M-CSF) | 2.3 | 3.0 | 11 | 0.0009 | 0.003 | ||||||||||||
| Tnfsf10 (TRAIL) | 1.1 | 4.0 | 9.7 | 0.002 | 0.005 | ||||||||||||
Genes shown are censored at FDR p ≤ 0.05 and log(2) fold change of ±1 and ordered by log fold change. CPM, counts per million; FDR, false discovery rate; LR, likelihood ratio.
Genes are differentially expressed in both humans and mice.
Figure 2Reactome Pathway Analysis of Activated MAIT Cells
Pathway analysis of human and murine activated MAIT cell transcriptomes.
(A and B) Human peripheral blood 5-OP-RU-stimulated MR1-5-OP-RU-tetramer+ MAIT cells compared with (A) naive CD8+CD45RA+ cells or (B) unstimulated MAIT cells.
(C and D) Murine pulmonary MR1-5-OP-RU-tetramer+ MAIT cells day 7 post infection with Legionella were compared with (C) naive CD8+CD44−CD62L+ T cells from uninfected mice or (D) MR1-tetramer+ MAIT cells from mice 12 weeks post infection with Legionella.
Plots show the extent to which named pathways from the curated Reactome database are upregulated. Color intensity represents statistical significance of the upregulation, dot size represents the number of genes upregulated in the pathway, x axis represents the proportion of all differentially expressed genes included in the pathway (“gene ratio”). n = 3 biological replicates per group performed once. Pathways were selected using a significance threshold of a log fold change >2 and p < 0.01.
Figure 3Comparison of Murine MAIT Cell Transcriptomes with Other Cells in Immunological Genome Project Dataset and with Commensal-Induced H2-M3-Restricted T Cells
Hierarchical clustering was used to compare transcriptomes of murine pulmonary MAIT cells or naive CD8+CD44−CD62L+ cells in this study with 88 other cell types deposited in the Immunological Genome Project (ImmGen) database and three cell types selected from Linehan et al., (2018) (gray lozenges). Figure shows a dendrogram (left), ImmGen identifiers (middle), and the full name of each cell type (right). Further details on cell types are presented in Table S2. ImmGen samples are identified in white lettering. Samples from the current study are identified in black lettering, with extended lozenges. Each cell type is represented by 2 to 3 replicates, identified by a numerical suffix, of which each replicate (“batch”) represents pooled tissue from three animals. Cell types are color coded: invariant natural killer T cells (iNKT, orange), natural killer (NK) cells (brown), γδ T cells (light green), innate lymphoid cells (ILC, dark green), conventional CD8 T cells (blue), and MAIT cells (purple). CD, clonal designation; NCR, NK cell receptor; Teff, effector T cell; Tmem, memory T cell.
Figure 4Gene Set Enrichment Analysis for Tissue Repair Gene Signature in Human and Murine MAIT Cells
(A–D) Gene set enrichment analysis (GSEA) was used to determine potential enrichment of a tissue repair signature (Linehan et al., 2018) in gene expression profiles from human (A and B) and murine (C and D) MAIT cells.
(A) GSEA summary plots for 5-OP-RU-stimulated human peripheral blood MAIT cells compared with unstimulated MAIT cells. The gene set is highly enriched: enrichment score (ES) = 0.62; normalized enrichment score (NES) = 1.38; nominal p value < 0.01; familywise error rate (FWER) p value < 0.01.
(B) Heatmap of expression of leading-edge subset genes within the gene set (red, highest expression; blue, lowest).
(C) GSEA summary plots for murine pulmonary MAIT cells 7 days post i.n. L. longbeachae infection (“Acute infection”), compared with MAIT cells 12 weeks post infection (“Resolved infection”). The gene set is highly enriched: enrichment score (ES) = 0.85; normalized enrichment score (NES) = 1.23; nominal p value < 0.01; familywise error rate (FWER) p value < 0.01.
(D) Heatmap of expression of leading-edge subset genes within the gene set (red, highest expression; blue, lowest). n = 3 biological replicates per group performed once.
Gene Set Enrichment Analysis for Tissue Repair Set
| Human Stimulated MAIT versus Unstimulated MAIT | Murine Acute Infection versus Resolved Infection | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Gene | Rank in Gene List | Rank Metric Score | Running Enrichment Score | Core Enrichment | Gene | Rank in Gene List | Rank Metric Score | Running Enrichment Score | Core Enrichment |
| CCL3 | 16 | 7.566 | 0.180 | yes | HBEGF | 5 | 12.242 | 0.162 | yes |
| TNF | 63 | 4.421 | 0.282 | yes | CSF2 | 33 | 11.994 | 0.319 | yes |
| CSF2 | 85 | 4.012 | 0.376 | yes | MMP25 | 97 | 7.929 | 0.417 | yes |
| VEGFA | 87 | 3.990 | 0.471 | yes | CXCL10 | 210 | 5.741 | 0.481 | yes |
| CSF1 | 105 | 3.700 | 0.559 | yes | AREG | 216 | 5.579 | 0.555 | yes |
| THBS1 | 226 | 2.790 | 0.614 | yes | JAG1 | 234 | 5.371 | 0.625 | yes |
| HIF1A | 594 | 1.725 | 0.618 | yes | TNF | 311 | 4.744 | 0.679 | yes |
| FURIN | 1,763 | 0.836 | 0.522 | no | PDGFB | 375 | 4.226 | 0.729 | yes |
| VEGFB | 2,560 | 0.539 | 0.456 | no | TGFB3 | 414 | 3.921 | 0.777 | yes |
| MMP28 | 3,207 | 0.339 | 0.399 | no | CXCL2 | 529 | 3.295 | 0.808 | yes |
| HMGB1 | 5,005 | −0.120 | 0.223 | no | FURIN | 721 | 2.474 | 0.820 | yes |
| PTGES2 | 5,279 | −0.189 | 0.200 | no | IL1B | 772 | 2.296 | 0.845 | yes |
| PDGFB | 5,399 | −0.218 | 0.194 | no | TGFB1 | 1,134 | 1.427 | 0.824 | no |
| TGFB1 | 5,973 | −0.374 | 0.146 | no | HIF1A | 1,464 | 1.033 | 0.802 | no |
| DISP1 | 6,691 | −0.589 | 0.088 | no | THBS1 | 1,761 | 0.801 | 0.780 | no |
| TGFA | 9,539 | −2.469 | −0.136 | no | VEGFB | 2,604 | 0.398 | 0.692 | no |
| MMP25 | 9,697 | −2.794 | −0.085 | no | HMGB1 | 3,518 | 0.118 | 0.594 | no |
| WNT1 | 10,012 | −4.987 | 0.003 | no | PTGES2 | 4,382 | −0.084 | 0.500 | no |
| DISP1 | 8,193 | −1.502 | 0.101 | no | |||||
Genes set enrichment analysis (GSEA) was used to determine potential enrichment of a tissue repair signature (Linehan et al., 2018) in gene expression profiles of 5-OP-RU-stimulated human peripheral blood MAIT cells compared with unstimulated MAIT cells (left) and of murine pulmonary MAIT cells 7 days post i.n. L. longbeachae infection, compared with MAIT cells 12 weeks post infection (right). Genes are ordered by their position in the list of genes ranked by their normalized enrichment score (ES). Running enrichment score: ES at this point in the ranked list of genes. Core enrichment genes contribute to the leading-edge subset of genes that contribute most to the enrichment result.
Genes are also significant in the equivalent analysis for murine MAIT cells.
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Anti Hu-CCR1 eFluor450; SF10B29; 1:100 | Biolegend | 362907; RRID: |
| Anti Hu-CCR2 FITC; K036C2; 1:100 | Biolegend | 357215; RRID: |
| Anti Hu-CCR4 PerCP Cy5.5; L291H4; 1:100 | Biolegend | 359405; RRID: |
| Anti Hu-CCR5 FITC; HEK/1/859; 1:100 | Biolegend | 313705; RRID: |
| Anti Hu-CCR6 APC; G034E3; 1:100 | Biolegend | 353415; RRID: |
| Anti Hu-CCR7 APC-Cy7; G043H7; 1:100 | Biolegend | 353212; RRID: |
| Anti Hu-CD3 PEAF 594; UCHT1; 1:200 | BD Bioscience | 562280; RRID: |
| Anti Hu-CD3 FITC; HIT3a; 1:80 | eBioscience | 11-0039-42; RRID: |
| Anti Hu-CD3 PE; OKT3; 1:20 | BD Bioscience | 555333; RRID: |
| Anti Hu-CD45RA APC; HI100; 1:50 | eBioscience | 48-0458-42; RRID: |
| Anti Hu-CD45RA FITC; HI100; 1:50 | BD Bioscience | 555488; RRID: |
| Anti Hu-CD8a PerCP Cy5.5; SK1; 1:100 | BD Bioscience | 565310; RRID: |
| Anti Hu-CD8α APC; RPA-T8; 1:80 | eBioscience | 17-0088-42; RRID: |
| Anti Hu-CD8β APC; 2ST8.5H7; 1:80 | BD Bioscience | 641058; RRID: |
| Anti Hu-CXCR4 BV421; 12G5; 1:100 | Biolegend | 306517; RRID: |
| Anti Hu-CXCR6 BV421 K041E5; 1:100 | Biolegend | 356013; RRID: |
| Anti Hu-GM-CSF PE; BVD2-21C11; 1:40 | Biolegend | 502305; RRID: |
| Anti Hu-IFN-γ AF700; B27; 1:80 | BD Bioscience | 557995; RRID: |
| Anti Hu-IFN-γ FITC; 25723.11; 1:50 | BD Bioscience | 340449; RRID: |
| Anti Hu-IL-10 PE; JES3-9D7; 1:40 | eBioscience | 12-7108-82; RRID: |
| Anti Hu-IL-17A PE-Cy7; eBio64DEC17; 1:50 | eBioscience | 25-7179-42; RRID: |
| Anti Hu-IL-17F AF488; Poly5166; 1:50 | Biolegend | 516603; RRID: |
| Anti Hu-LIF APC; REA350; 1:50 | Miltenyi | 130-105-513; RRID: |
| Anti Hu-TCR Vα7.2 APC; 3C10; 1:50 | Biolegend | 351708; RRID: |
| Anti Hu-TNF PE; mAb11; 1:50 | eBioscience | 12-7349-41; RRID: |
| Anti Ms-CD19 PerCP-Cy5.5; ID3; 1:200 | BD Bioscience | 551001; RRID: |
| Anti Ms-CD4 APC-Cy7; GK1.5; 1:200 | BD Bioscience | 552051; RRID: |
| Anti Ms-CD44 AF700; IM7; 1:50 | BD Bioscience | 560567; RRID: |
| Anti Ms-CD45.2 FITC; 104; 1:200 | BD Bioscience | 553772; RRID: |
| Anti Ms-CD62L BV605; Mel-14; 1:100 | BD Bioscience | 563252; RRID: |
| Anti Ms-CD8α PE; 53-6.7; 1:800 | BD Bioscience | 553032; RRID: |
| Anti Ms-CSF2 (GM-CSF) APC; MP1-22E9; 1:150 | Biolegend | 505414; RRID: |
| Anti Ms-GITRL (TNFSF18) PE; YGL386; 1:150 | Biolegend | 120305; RRID: |
| Anti Ms-IFN-γ PE; XMG1.2; 1:200 | BD Bioscience | 554412; RRID: |
| Anti Ms-IFN-γ PE-Cy7; XMG1.2; 1:400 | BD Bioscience | 557649; RRID: |
| Anti Ms-IL-10 PE; JES5-16E3; 1:300 | eBioscience | 12-7101-81; RRID: |
| Anti Ms-IL-17A APC; 17B7; 1:25 | eBioscience | 17-7177-81; RRID: |
| Anti Ms-IL-17F PE; 316016; 1:200 | R&D | IC2057P; RRID: |
| Anti Ms-TCRβ APC; H57-597; 1:200 | BD Bioscience | 561080; RRID: |
| Anti Ms-TCRβ PE; H57-597; 1:200 | BD Bioscience | 561081; RRID: |
| Anti Ms-TCRβ PE CF594; H57-597; 1:200 | BD Bioscience | 562841; RRID: |
| Anti Ms-TNF PE; MP6-XT22; 1:300 | BD Bioscience | 554419; RRID: |
| Anti Ms-TRANCE (TNFSF11)PE; IK22/5; 1:150 | Biolegend | 510005; RRID: |
| Clinical isolate NSW150 ( | N/A | |
| Healthy adult peripheral human blood mononuclear cells | Volunteer participants, Royal Melbourne Hospital | Ethics ID 2002.107 |
| Pam3CSK4 | Invivogen | # tlrl-Pam3CSK4 |
| Heat Killed | Invivogen | # tlrl-hklm |
| Poly I:C (high molecular weight) | Invivogen | # tlrl-Poly(I:C)(HMW) |
| Poly I:C (low molecular weight) | Invivogen | # tlrl-Poly(I:C)(LMW) |
| Lipopolysaccharide from | Enzo life sciences | ALX-581-012-L001 |
| Flagellin from | Invivogen | TLRL-EPSTELA |
| FSL-1 (Pam2CGDPKHPKSF) | Invivogen | # tlrl-FSL-1 |
| Pam2Cys | Synthesized in house | N/A |
| Imiquimod | Novus biologicals | NBP2-26228 |
| CpG ODN1826 | Invivogen | # tlrl-ODN1826 |
| Absolutely RNA Microprep Kit | Agilent | #400805 |
| Fixation/Permeabilization Solution Kit | BD Biosciences | 554714 |
| QIAshredder | QIAGEN | 79654 |
| Bioanalyzer 2100 RNA pico kit | Agilent | 5067-1512, 5067-1529, 5067-1511 |
| Nextera XT library preparation | Illumina | FC-131-1002 |
| AMPure XP | Beckman Coulter | A63880 |
| SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing | Clontech | 634894 |
| RNA Sequencing dataset ‘Transcriptome of activated human and mouse MAIT cells’ are deposited in Gene Expression Omnibus | This paper | GSE123805 |
| Mouse: C57BL/6 | Biological Research Facility, Peter Doherty Institute, Melbourne | N/A |
| CpG 1668 T∗C∗C∗A∗T∗G∗A∗C∗G∗T∗T∗C∗C∗T∗G∗A∗T∗G∗C∗T (∗phosphorothioate linkage) | Geneworks | N/A |
| MR1 5′ 8763-8783 AGC TGA AGT CTT TCC AGA TCG | Geneworks | 1204410 |
| MR1 9188-9168 rev ACA GTC ACA CCT GAG TGG TTG | Geneworks | 1204411 |
| MR1 10451-10431 GAT TCT GTG AAC CCT TGC TTC | Geneworks | 1204412 |
| STAR Aligner Software | ||
| R package | ||
| GSEA version 3.0 | ||
| Prism GraphPad software (version 7.0) | GraphPad Software, San Diego, CA | |
| FlowJo10 software | TreeStar, Ashland, OR | |
| Partek Flow | Partek Incorporated, St Louis, MO | |